Search

Your search keyword '"Matthews, Gail"' showing total 971 results

Search Constraints

Start Over You searched for: Author "Matthews, Gail" Remove constraint Author: "Matthews, Gail"
971 results on '"Matthews, Gail"'

Search Results

1. Improvement of immune dysregulation in individuals with long COVID at 24-months following SARS-CoV-2 infection

2. SARS-CoV-2 cross-sectional serosurvey across three HIV-1 therapeutic clinical trials in Africa

3. Changes in incidence of hepatitis C virus reinfection and access to direct-acting antiviral therapies in people with HIV from six countries, 2010–19: an analysis of data from a consortium of prospective cohort studies

4. Cross-sectional and longitudinal genotype to phenotype surveillance of SARS-CoV-2 variants over the first four years of the COVID-19 pandemic

5. The Association of Baseline Plasma SARS-CoV-2 Nucleocapsid Antigen Level and Outcomes in Patients Hospitalized With COVID-19

6. Evaluating Primary Endpoints for COVID-19 Therapeutic Trials to Assess Recovery.

7. Efficacy and Safety of Ensovibep for Adults Hospitalized With COVID-19

8. Lessons from an international trial evaluating vaccination strategies for recovered inpatients with COVID-19 (VATICO).

10. Lack of association between classical HLA genes and asymptomatic SARS-CoV-2 infection

11. Direct-acting antiviral therapies for hepatitis C infection: global registration, reimbursement, and restrictions

14. Intravenous aviptadil and remdesivir for treatment of COVID-19-associated hypoxaemic respiratory failure in the USA (TESICO): a randomised, placebo-controlled trial

15. Hepatitis C virus transmission between eight high-income countries among men who have sex with men: a whole-genome analysis

16. Patient-Reported Outcomes During and After Hepatitis C Virus Direct-Acting Antiviral Treatment Among People Who Inject Drugs

17. Sofosbuvir/velpatasvir for 12 vs. 6 weeks for the treatment of recently acquired hepatitis C infection

18. Emergence and antibody evasion of BQ, BA.2.75 and SARS-CoV-2 recombinant sub-lineages in the face of maturing antibody breadth at the population level

19. Treatment as prevention effect of direct-acting antivirals on primary hepatitis C virus incidence: findings from a multinational cohort between 2010 and 2019

22. Reinfection incidence and risk among people treated for recent hepatitis C virus infection

23. SARS-CoV-2 Omicron BA.5: Evolving tropism and evasion of potent humoral responses and resistance to clinical immunotherapeutics relative to viral variants of concern

24. Tixagevimab–cilgavimab for treatment of patients hospitalised with COVID-19: a randomised, double-blind, phase 3 trial

26. Platform for isolation and characterization of SARS-CoV-2 variants enables rapid characterization of Omicron in Australia

29. Characteristics of hepatitis C virus resistance in an international cohort after a decade of direct-acting antivirals

30. Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO): a randomised controlled trial

31. Unsuccessful Direct Acting Antiviral Hepatitis C Treatment Among People With HIV: Findings From an International Cohort.

32. Control and Elimination of Hepatitis C Virus Among People With HIV in Australia: Extended Follow-up of the CEASE Cohort (2014–2023).

35. Associations between antiretroviral regimen and changes in blood pressure: results from the D2EFT study

36. Age-related clonal hematopoiesis and HIV infection are associated with geriatric outcomes: The ARCHIVE study

37. A point-of-care lateral flow assay for neutralising antibodies against SARS-CoV-2

39. A molecular transmission network of recent hepatitis C infection in people with and without HIV: Implications for targeted treatment strategies

40. Availability of point-of-care HBV tests in resource-limited settings

43. High end‐of‐treatment hepatitis B core‐related antigen levels predict hepatitis flare after stopping nucleot(s)ide analogue therapy.

44. Psychiatric sequelae after SARS-Cov-2 infection: trajectory, predictors and associations in a longitudinal Australian cohort.

47. Changes in incidence of hepatitis C virus reinfection and access to direct-acting antiviral therapies in people with HIV from six countries, 2010–19: an analysis of data from a consortium of prospective cohort studies

48. Simplified monitoring for hepatitis C virus treatment with glecaprevir plus pibrentasvir, a randomised non-inferiority trial

49. Risk of Primary Incident Hepatitis C Infection Following Bacterial Sexually Transmissible Infections Among Gay and Bisexual Men in Australia From 2016 to 2020

50. Direct-acting antiviral therapies for hepatitis C infection: global registration, reimbursement, and restrictions

Catalog

Books, media, physical & digital resources